Management of Hepatitis C Virus Infection in Heavy Drinkers

Unité d'Hépatologie et d'Addictologie, Hôpital Cochin, Assistance Publique des Hôpitaux de Paris, 27 rue du faubourg Saint Jacques, 75014 Paris, France.
Alcohol and Alcoholism (Impact Factor: 2.89). 03/2013; 48(3). DOI: 10.1093/alcalc/agt020
Source: PubMed


AimOptimal management of hepatitis C virus (HCV) infection is controversial in heavy drinkers. We compared the management of HCV infection of heavy drinkers with that of patients without a history of alcohol abuse.Methods
In a retrospective case-control study, 69 HCV-infected heavy drinkers [daily alcohol consumption at referral above 60 g/day, hereafter 'alcohol group'] were compared with matched HCV-infected patients with low alcohol consumption (<40 g/day, 'control group').ResultsPatients of the 'alcohol group' were younger (42 vs. 45 years, P = 0.05), more often male (69.6 vs. 56.5%, P = 0.11) and had been infected by intravenous drug use (85.5 vs. 45.0%, P < 0.0001). The percentage of patients with a recommendation for treatment according to the French 2002 consensus (bridging fibrosis or genotype 2 or 3) was 52 of 69 (75.4%) in both groups, while the proportion of patients treated was higher in the control group (71.0 vs. 44.9%, P = 0.002). In the 'alcohol group', patients had better access to treatment if they were employed or consumed 170 g/day or less at first referral. Sustained virological response (SVR) was obtained in 10 of 31 patients (32.3%) of the 'alcohol group' vs. 8 of 31 patients (25.8%) of the control group matched for genotype and type of treatment (P = 0.58).Conclusion
Heavy drinkers are less often considered for antiviral therapy compared with patients without a history of alcohol abuse. However, once treatment is actually initiated, SVR rates are comparable with those achieved in non-drinkers despite the continuation of alcohol consumption during therapy in some patients.

Download full-text


Available from: Stéphane Darbeda, Jul 26, 2014
  • Source

    Alimentary Pharmacology & Therapeutics 06/2013; 37(11):1118-9. DOI:10.1111/apt.12321 · 5.73 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The introduction of interferon-free regimens for the treatment of chronic hepatitis C virus (HCV) infection represents a key turn in hepatology because of their extremely high therapeutic efficacy and relatively safe use also in "difficult-to-treat" and/or "difficult-to-cure" HCV subgroups, including patients with cirrhosis. Due to treatment guidelines based on health economics, patients with cirrhosis will likely represent the frontline in the use of the new anti-HCV agents. Accordingly, this article concentrates on the effect of sustained viral response (SVR) following antiviral treatment for HCV on the evolution of tissue fibrosis and cirrhosis, and more importantly, on the clinical consequences of viral eradication, particularly in patients in which SVR has been achieved in an advanced stage of the disease. In this context, the assessment of fibrosis regression and possibly of cirrhosis reversal will represent the diagnostic challenge of the next decade. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
    Seminars in Liver Disease 05/2015; 35(2):157-65. DOI:10.1055/s-0035-1550056 · 4.95 Impact Factor